|
|
|
|
Low plasma levels of apoE are associated with increased risk of future Alzheimer disease and all dementia in the general population, independent of e2/e3/e4 APOE genotype. This is clinically relevant, because no plasma biomarkers are currently implemented. Hence, plasma levels of apoE may be a new, easily accessible preclinical biomarker. |
|